Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard

Sahar Saeed, Sheila F. O’Brien, Kento Abe, QiLong Yi, Bhavisha Rathod, Jenny Wang, Mahya Fazel-Zarandi, Ashleigh Tuite, David Fisman, Heidi Wood, Karen Colwill, Anne-Claude Gingras, Steven Drews
doi: https://doi.org/10.1101/2021.05.11.21256992

Article usage

Article usage: May 2021 to July 2025

AbstractFullPdf
May 2021543290
Jun 202186842
Jul 202180612
Aug 20211232131
Sep 2021571019
Oct 202170726
Nov 2021491019
Dec 202165135
Jan 20223873
Feb 20221916
Mar 20221932
Apr 20222374
May 202221210
Jun 20222538
Jul 20221921
Aug 20221815
Sep 20223435
Oct 20222316
Nov 20221023
Dec 20221415
Jan 20232061
Feb 20231473
Mar 20231510
Apr 20231913
May 20231318
Jun 2023748
Jul 2023634
Aug 202318116
Sep 20231444
Oct 20231014
Nov 202315713
Dec 20231402
Jan 20241304
Feb 20241543
Mar 2024932
Apr 20241365
May 2024837
Jun 20241436
Jul 2024746
Aug 20241329
Sep 20241425
Oct 20241432
Nov 20241252
Dec 2024997
Jan 20257113
Feb 20258279
Mar 2025252011
Apr 20251688
May 202512610
Jun 202529187
Jul 202516138
Back to top
Posted May 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard
Sahar Saeed, Sheila F. O’Brien, Kento Abe, QiLong Yi, Bhavisha Rathod, Jenny Wang, Mahya Fazel-Zarandi, Ashleigh Tuite, David Fisman, Heidi Wood, Karen Colwill, Anne-Claude Gingras, Steven Drews
medRxiv 2021.05.11.21256992; doi: https://doi.org/10.1101/2021.05.11.21256992
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area